You are on page 1of 3

CQRC Concerned with Inclusion of Home Ventilators in Competitive Bidding

Program

CQRC reiterates its support for much-needed reforms to Competitive Bidding Program (CBP), but
opposes the inclusion of home ventilators out of concern for vulnerable patient population.

Washington, DC, December 05, 2018 --(PR.com)-- The Council for Quality Respiratory Care (CQRC) -
a coalition of the nation's leading home oxygen therapy provider and manufacturing companies - today
reiterated its support for the Centers for Medicare & Medicaid Services' key reforms to stabilize the
market for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) including home
respiratory therapy and supplies, but expressed concern over a sub-regulatory proposal to include home
ventilators in the Competitive Bidding Program (CBP).

In a letter to CMS Administrator Seema Verma, the CQRC praised CMS for reforming the CBP so the
price of DMEPOS is determined using a lead-item pricing methodology, rather than the flawed median
bid methodology, which caused half of all providers to accept reimbursement rates below their maximum
bids.

However, the letter expressed serious reservations about the inclusion of home ventilators in the CBP
because of concern about whether the new program would be interpreted to incorporate home ventilators,
which are used by the most fragile home respiratory beneficiaries.

“The CQRC is deeply troubled and confused by the proposal to add three types of ventilation devices,
which are used by highly vulnerable Medicare beneficiaries who otherwise could not remain in their
homes, to the competitive bidding program before the modified policies have been implemented,” the
letter states.

Advancements in home ventilation have helped improve the quality of life and healthcare outcomes for
Medicare beneficiaries who require such treatments to survive and would otherwise rely on
institutionalized care. In addition to allowing patients to be treated in the comfort of their own homes, the
letter highlights research that shows the use of non-invasive ventilators has created clinical benefits that
lower rates of morbidity and mortality, as well as a reduction in Part A costs.

Unfortunately, the inclusion of home ventilators in the CBP could impede patient access to these
lifesaving therapies by requiring these patients to rely upon the lowest bidders before the new
methodology has been tested. As CMS starts to implement reforms that make it more likely for home
oxygen supplies and equipment to reflect true market pricing, it is unclear how the updated CBP
methodology will address unresolved issues, such as capacity, how information will be used to set rates,
and the relationship between lead items and non-lead items in each product category. Moreover,
researchers have argued that one of the rationales for subjecting home ventilators to competitive bidding
-- concerns about overutilization -- is largely unfounded as the recent rise in usage is owed far more to
technological and clinical advancements than fraudulent overutilization.

Page 1/3
PR.com Press Release Distribution Terms of Use
Therefore, the CQRC argues it would not be appropriate for the Competitive Bidding Program to set rates
for home ventilation at this time.

“It is premature to subject a vulnerable population that will die without access to home ventilation therapy
to the growing pains the new methodology will cause during the first rounds of its implementation,” the
letter said.

About the Council for Quality Respiratory Care


The CQRC is a coalition of the nation's seven leading home oxygen therapy provider and manufacturing
companies. To learn more, visit cqrc.org and follow CQRC on Twitter at @TheCQRC.

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
The Council for Quality Respiratory Care
Ellen Almond
703-548-0019
Contact via Email
http://cqrc.org/

Online Version of Press Release:


You can read the online version of this press release at: https://www.pr.com/press-release/771710

Page 3/3
PR.com Press Release Distribution Terms of Use